[go: up one dir, main page]

AU2001236782A1 - 34p3d7: a tissue specific protein highly expressed in prostate cancer - Google Patents

34p3d7: a tissue specific protein highly expressed in prostate cancer

Info

Publication number
AU2001236782A1
AU2001236782A1 AU2001236782A AU3678201A AU2001236782A1 AU 2001236782 A1 AU2001236782 A1 AU 2001236782A1 AU 2001236782 A AU2001236782 A AU 2001236782A AU 3678201 A AU3678201 A AU 3678201A AU 2001236782 A1 AU2001236782 A1 AU 2001236782A1
Authority
AU
Australia
Prior art keywords
prostate cancer
specific protein
highly expressed
tissue specific
protein highly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001236782A
Inventor
Daniel E. H. Afar
Pia M. Challita-Eid
Mary Faris
Rene S. Hubert
Aya Jakobovits
Elana Levin
Steve Chappell Mitchell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agensys Inc
Original Assignee
Urogenesys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Urogenesys Inc filed Critical Urogenesys Inc
Publication of AU2001236782A1 publication Critical patent/AU2001236782A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G01N33/57585
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G01N33/57555
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2001236782A 2000-02-08 2001-02-08 34p3d7: a tissue specific protein highly expressed in prostate cancer Abandoned AU2001236782A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18102000P 2000-02-08 2000-02-08
US60181020 2000-02-08
PCT/US2001/004094 WO2001059110A2 (en) 2000-02-08 2001-02-08 34p3d7: a tissue specific protein highly expressed in prostate cancer

Publications (1)

Publication Number Publication Date
AU2001236782A1 true AU2001236782A1 (en) 2001-08-20

Family

ID=22662558

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001236782A Abandoned AU2001236782A1 (en) 2000-02-08 2001-02-08 34p3d7: a tissue specific protein highly expressed in prostate cancer

Country Status (3)

Country Link
US (1) US20020150972A1 (en)
AU (1) AU2001236782A1 (en)
WO (1) WO2001059110A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020127578A1 (en) * 2000-11-27 2002-09-12 Susana Salceda Compositions and methods relating to prostate specific genes and proteins
WO2003085121A2 (en) * 2002-04-01 2003-10-16 Agensys, Inc. Nucleic acid and corresponding protein entitled 213p1f11 useful in treatment and detection of cancer
GB201520550D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520568D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd Peptides

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002520054A (en) * 1998-07-14 2002-07-09 コリクサ コーポレイション Compositions and methods for treatment and diagnosis of prostate cancer
AU5047800A (en) * 1999-05-28 2000-12-18 Ludwig Institute For Cancer Research Breast, gastric and prostate cancer associated antigens and uses therefor
EP1074617A3 (en) * 1999-07-29 2004-04-21 Research Association for Biotechnology Primers for synthesising full-length cDNA and their use

Also Published As

Publication number Publication date
US20020150972A1 (en) 2002-10-17
WO2001059110A3 (en) 2002-02-21
WO2001059110A2 (en) 2001-08-16

Similar Documents

Publication Publication Date Title
AU2002258990A1 (en) Improvements in ablation therapy
AU2001253140A1 (en) Tumor markers in ovarian cancer
AU2002211835A1 (en) Oncology tissue microarrays
WO2001016852A8 (en) User interface for semi-fungible trading
AU2002230860A1 (en) Skin desinfectant applicator
AU2003235470A1 (en) Predictive markers in cancer therapy
AU2001251348A1 (en) Apparatus for sensing human prostate tumor
AU2001249626A1 (en) Cathepsin inhibitors in cancer treatment
AU2001259702A1 (en) Tissue regrafting
IL206604A0 (en) Transmembrane protein expressed in prostate cancer
AU2001290860A1 (en) Spas-1 cancer antigen
AU2001285232A1 (en) Alpha-difluoromethylornithine (dfmo) use in the human prostate
AU2002362613A1 (en) Galectins-1-and-4 in tumor development
AU2001286721A1 (en) Human interleukin-four induced protein
AU2001257325A1 (en) Cancer treatment
AU2002227925A1 (en) Human beta-defensin-3
AU2001288921A1 (en) Human breast cancer biomarkers
AU8026300A (en) Sodd gene expression in cancer
AU2002215111A1 (en) Ruthenium-aryl-compounds in cancer therapy
AU2001236782A1 (en) 34p3d7: a tissue specific protein highly expressed in prostate cancer
AU6111800A (en) 26 human prostate and prostate cancer associated proteins
AU2001238144A1 (en) 83p5g4: a tissue specific protein highly expressed in prostate cancer
AU2001244863A1 (en) Apoptin-associating protein
AU2001289127A1 (en) Tumor treatment
AU2001268466A1 (en) 55p4h4: gene expressed in various cancers